

Saudi Arabia Hepatitis Country profile 2017

Epidemiology

HCV

Estimated Prevalence: 0.34%

Estimated no of carriers: **105,000**

HCV mean prevalence among PWID: **56.6 [38.3-74.0]**

HBV

Above 5 yrs old

Prevalence: 2.24%

Estimate no of carriers: 636,000

Below 5 yrs old

Prevalence: **0.3%**

Estimate no of carriers: **10,000**

Governance

Presence of a focal point **Yes**

Presence of STAG **Yes**

Involvement of civil society **No**

Units to implement national response **Yes**

NSP (published or drafted) **Yes**

Estimating cost to implement the NSP **Yes**

Fund available for the NSP **No**

Impact targets set **Yes**

Service coverage targets set **Yes**

Policies for stigma and discrimination **Yes**

A system for Hepatitis prevention, testing, care and treatment services integrated at community, primary, secondary and tertiary care levels has been defined **Yes**

Core hepatitis competencies of different cadres of health workers at different levels of the health system been defined considering task shifting options **Yes**

Training and supervisory needs of health workers been defined **Yes**

An investment case for an enhanced viral hepatitis response been developed ** **No**

A specific portion of National health budget had been allocated to viral hepatitis prevention, care and treatment? **Yes**

A set of essential viral hepatitis interventions been defined to be included in the national social / health insurance package **Yes**

FP*: Future plans

Surveillance

National surveillance system for viral hepatitis **Yes**

An inventory of existing data and sources of data on viral hepatitis been made **Yes**

Testing policies and guidelines

Official guidance on which test to use for diagnosing HBV and/or HCV **Yes**

Official guidance on testing pregnant women for HBV **Yes**

Official guidance on testing people who inject drugs (PWID) for HCV **Yes**

Official guidance or protocols for all people diagnosed with HBV and/or HCV to be routinely referred for treatment and care **Yes**

National coverage targets been set for the following indicators Hepatitis B testing coverage of selected populations **Yes**

Hepatitis C testing coverage of selected populations **Yes**

Presence of national policies and guidelines for priority interventions available and in line with global standards for the following Policies for screening of selected population groups at increased risk **Yes**

A policy for mandatory screening of all blood donations for Hepatitis B and C **Yes**

A policy for referral of all blood donors with positive screening results for Hepatitis B and C confirmatory testing and case management **Yes**

Guidelines for diagnostic testing for Hepatitis B **Yes**

Guidelines for diagnostic testing for Hepatitis C **Yes**

Baseline values been determined for the following global indicators Percentage of blood donors screened for Hepatitis B and C **Yes**

Percentage of health facilities that implement the policy of 100% single use (or safety engineered) injection devices **Yes**

Infrastructure for testing

Number of facilities that are able to offer serological testing for both HBV (i.e. HBsAg) and HCV (i.e. Anti-HCV) **Number of facilities that are able to offer nucleic acid testing (NAT) for both HBV (i.e. HBV DNA) and HCV (i.e. HCV RNA)**

| Primary level (i.e. health centers, community outreach) | Secondary level/Tertiary level (i.e. hospitals) | Primary level (i.e. health centers, community outreach) | Secondary level/Tertiary level (i.e. hospitals) |
|---|---|---|---|
| Private Sector Polyclinics | Total no. of 2ry and 3ry hospitals | None | All |

Private Sector Polyclinics **None**

Total no. of 2ry and 3ry hospitals **All**

Saudi Arabia Hepatitis Country profile 2017

Treatment policies and guidelines

| | |
|--|-----|
| Tenofovir or Entecavir as the first line of treatment for HBV | Yes |
| Anti-nucleoside/nucleotide analogues are available for the treatment of hepatitis B | BGP |
| interferon-free (INF-free) direct-acting antiviral (DAA) are the regimens considered the first line of treatment for patients with chronic hepatitis C | Yes |
| Current treatment policy for people with chronic HCV | LA |
| Current situation in terms of registration of Tenofovir or Entecavir specifically for HBV infection | Yes |
| Current situation in terms of registration of medicines used in IFN-free DAA regimens for HCV infection | Yes |
| Tender (national or multinational) to launch price negotiations with pharmaceutical companies for HBV and/or HCV treatment | Yes |
| Hepatitis B treatment coverage | Yes |
| Hepatitis C treatment coverage | Yes |
| Guidelines for Hepatitis B treatment | Yes |
| Guidelines for Hepatitis C treatment | Yes |
| A strategy for achieving the best price for medicines and diagnostics been formulated and pursued | Yes |

Treatment Estimates

| | |
|--|----|
| Estimate of the total number of people on antiviral treatment for HBV for the years 2013 | NA |
| Estimate of the total number of people on antiviral treatment for HBV for the years 2015 | NA |
| Estimate of the total number of people initiated on antiviral treatment for HCV for the years 2013 | NA |
| Estimate of the total number of people initiated on antiviral treatment for HCV for the years 2015 | NA |
| Estimate of the total number of people planned and budgeted for treatment of HBV infection in 2017 | NA |
| Estimate of the total number of people planned and budgeted for treatment of HCV infection in 2017 | NA |

FP*: Policy not established, but plan is to establish one by 2017

Yes**: One or more of these medicines have been registered but only for HCV

Prevention

| | | |
|--|--|-----|
| National coverage targets been set for the following indicators | Hepatitis B vaccination of health workers | Yes |
| | Safe injections in health care settings | Yes |
| | Targets for number of needles-syringes distributed to PWID per year | Yes |
| Presence of national policies and guidelines for priority interventions available and in line with global standards for the following | A policy for Hepatitis B vaccination of health workers | Yes |
| | A policy to integrate Hepatitis B vaccination in services targeting people who inject drugs, men who have sex with men and sex workers | No |
| | A policy for use of safe injections (or safety engineered devices) in health care settings to prevent transmission of blood borne infections | Yes |
| Baseline values been determined for the following global indicators | Coverage of hepatitis B vaccination of health workers, | Yes |
| | For countries with significant PWID populations, coverage of needles-syringe distribution | Yes |
| | For countries with significant PWID populations, HBV vaccination | Yes |

HCV Elimination Targets

| | 2017 | 2019 | 2020 |
|--------------------------------------|------|-----------|------|
| Prevalence of Chronic HCV (%) | | | |
| Chronic HCV (N) | | | |
| Diagnosed with HCV (%) | | NA | |
| Diagnosed with HCV (N) | | | |
| HCV patients treated (%) | | | |
| HCV patients treated (N) | | | |
| Number of new infections | | | |